Capital Markets 2023
HKEX IPO of mainland technology company
Acted for the underwriters on the HKEX IPO of a mainland technology company, with a concurrent Reg S placement.
Oversubscribed 12x; listing raised HK$9.3 billion.
People / Sarah Chen
Bio
Sarah Chen is the partner chairing the firm's Asia capital markets practice. She has led IPOs on the HKEX, SGX, and NYSE, with an aggregate deal value exceeding $25 billion. Her recent mandates include the Hong Kong listing of a mainland technology company and a dual-primary listing on the HKEX and NYSE.
Sarah joined the firm in 2003 and opened the Hong Kong office in 2009. She is listed in major directories for both capital markets and M&A.
Matters (3)
-
- Capital Markets 2024
Dual-primary listing on HKEX and NYSE
Acted for the issuer on a dual-primary listing on the HKEX and NYSE, navigating conflicting disclosure standards and concurrent SEC review.
Listed with $2.1B raised across both exchanges.
- Mergers & Acquisitions 2023
Cross-border acquisition of pharma target with IP and tax structuring
Acted for a U.S. pharma acquirer on the acquisition of an Asia-based target, with concurrent IP and tax structuring across seven jurisdictions.
Closed with full step-up in basis and IP ownership consolidated in holding company.